Clinical trials: in Finland
Hemophilia
The Dynamic Interplay Between Bleeding Phenotype and Baseline Factor Level in Moderate and Mild Hemophilia A and B
There are large inter-individual differences in the bleeding pattern of patients with moderate or mild hemophilia. The major determinant of bleeding phenotype is the level of coagulant factor VIII or IX.
- Trial name
- DYNAMO (NCT03623295)
- Testing
- Blood sample, Questionnaire, MRI-imaging
- Where
- 17 sites in Australia, Austria and 8 more
- Volunteers
- 304 people
- Sponsor
- Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)
Asymptomatic Amyloid-positive
An Efficacy and Safety Study of Atabecestat in Participants Who Are Asymptomatic at Risk for Developing Alzheimer's Dementia
The purpose of this study is to evaluate whether treatment with atabecestat slows cognitive decline compared with placebo treatment, as measured by a composite cognitive measure, the Preclinical Alzheimer Cognitive Composite…
- Trial name
- EARLY (NCT02569398)
- Testing
- Atabecestat, 5 mg, Atabecestat, 25 mg
- Where
- 128 sites in United States, Australia and 11 more
- Volunteers
- 557 people, healthy volunteers welcome
- Sponsor
- Janssen Research & Development, LLC
Depressive Disorder, Treatment-Resistant
A Study to Evaluate the Efficacy, Safety, and Tolerability of Intranasal Esketamine Plus an Oral Antidepressant in Elderly Participants With Treatment-resistant Depression
The purpose of this study is to evaluate the efficacy and safety of switching elderly participants with treatment-resistant depression (TRD) from a prior antidepressant treatment (to which they have not responded) to either…
- Trial name
- TRANSFORM-3 (NCT02422186)
- Testing
- Esketamine, Duloxetine (Oral Antidepressant), Escitalopram (Oral Antidepressant)
- Where
- 69 sites in United States, Belgium and 10 more
- Volunteers
- 139 people
- Sponsor
- Janssen Research & Development, LLC
Depressive Disorder, Treatment-Resistant
A Long-term Safety Study of Esketamine Nasal Spray in Treatment-resistant Depression
The purpose of this study is to assess the safety and tolerability of esketamine nasal spray in participants with treatment-resistant depression (TRD).
- Trial name
- SUSTAIN-3 (NCT02782104)
- Testing
- Esketamine Nasal Spray
- Where
- 173 sites in United States, Argentina and 24 more
- Volunteers
- 1,148 people
- Sponsor
- Janssen Research & Development, LLC
Treatment-resistant Depression
A Long-term, Safety and Efficacy Study of Intranasal Esketamine in Treatment-resistant Depression
The purpose of this open-label, multicenter study is to assess the long term safety and efficacy of intranasal esketamine plus an oral antidepressant in participants with treatment-resistant depression (TRD).
- Trial name
- SUSTAIN-2 (NCT02497287)
- Testing
- Esketamine (Intranasal Spray), Duloxetine (Oral Antidepressant), Escitalopram (Oral Antidepressant)
- Where
- 109 sites in United States, Argentina and 19 more
- Volunteers
- 802 people
- Sponsor
- Janssen Research & Development, LLC
Depressive Disorder, Major
A Long-term Comparison of Esketamine Nasal Spray Versus Quetiapine Extended Release, Both in Combination With a Selective Serotonin Reuptake Inhibitor/Serotonin-Norepinephrine Reuptake Inhibitor, in Participants With Treatment Resistant Major Depressive Disorder
The primary purpose of this study is to evaluate the efficacy of flexibly dosed esketamine nasal spray compared with quetiapine extended-release (XR), both in combination with a continuing selective serotonin reuptake…
- Trial name
- ESCAPE-TRD (NCT04338321)
- Testing
- Esketamine 28 mg, Esketamine 56 mg, Esketamine 84 mg
- Where
- 171 sites in Argentina, Austria and 22 more
- Volunteers
- 676 people
- Sponsor
- Janssen-Cilag International NV
Depressive Disorder, Major
A Study to Evaluate the Efficacy and Safety of JNJ-42847922 as Adjunctive Therapy to Antidepressants in Adult Participants With Major Depressive Disorder Who Have Responded Inadequately to Antidepressant Therapy
The purpose of this study is to assess the dose-response relationship of 2 doses of JNJ-42847922 before interim analysis, and potentially 3 doses based on interim analysis results, compared to placebo as adjunctive therapy to an…
- Trial name
- NCT03227224
- Testing
- JNJ-42847922
- Where
- 101 sites in United States, Bulgaria and 6 more
- Volunteers
- 287 people
- Sponsor
- Janssen Research & Development, LLC
Malignant Melanoma
Study of Dabrafenib+Trametinib in the Adjuvant Treatment of Stage III BRAF V600+ Melanoma After Complete Resection to Evaluate the Impact on Pyrexia Related Outcomes
The main purpose of this study was to evaluate the impact on pyrexia-related outcomes of an adapted pyrexia adverse event (AE)-management algorithm, as well as safety, efficacy and health-related outcomes.
- Trial name
- COMBI-APlus (NCT03551626)
- Testing
- Dabrafenib, Trametinib
- Where
- 100 sites in Argentina, Australia and 21 more
- Volunteers
- 552 people
- Sponsor
- Novartis Pharmaceuticals
Schizophrenia
An Efficacy, Safety And Tolerability Study of Flexibly Dosed Paliperidone Extended Release (ER) in Participants With Schizophrenia
The purpose of this study is to explore tolerability, safety and effectiveness of flexibly dosed paliperidone extended release (ER) in participants with schizophrenia (psychiatric disorder with symptoms of emotional instability…
- Trial name
- PERFlexS (NCT00460512)
- Testing
- Paliperidone ER
- Where
- 231 sites in Belgium, Bulgaria and 20 more
- Volunteers
- 1,814 people
- Sponsor
- Janssen-Cilag International NV
Severe Mental Illness
Effectiveness of Mentalization-based Therapy (MBT)
The effects of psychological treatment, mentalization-based therapy, will be studied among persons with mental disorders seeking help from mental health care services.
- Trial name
- NCT06659211
- Testing
- Mentalisation-Based Therapy, Treatment as Usual (TAU)
- Where
- Finland
- Volunteers
- 128 people
- Sponsor
- Oulu University Hospital
Tonsillar Hypertrophy, Sleep Apnea, Obstructive
Intracapsular Tonsillectomy in the Treatment of Obstructive Sleep Apnea in Adults
Treating sleep apnea in adults caused by tonsillar hypertrophy with intracapsular tonsillectomy by coblation
- Trial name
- NCT04314492
- Testing
- Tonsillectomy
- Where
- 2 sites in Finland
- Volunteers
- 25 people
- Sponsor
- Turku University Hospital
Advanced Cancer
First-In-Human Study of Monoclonal Antibody BMS-986218 by Itself and in Combination With Nivolumab in Participants With Advanced Solid Tumors
The purpose of this study is to determine whether BMS-986218 both by itself and in combination with Nivolumab is safe and tolerable in the treatment of advanced solid tumors.
- Trial name
- NCT03110107
- Testing
- Ipilimumab, BMS-986218, Nivolumab
- Where
- 52 sites in United States, Argentina and 15 more
- Volunteers
- 376 people
- Sponsor
- Bristol-Myers Squibb
Non-alcoholic Fatty Liver Disease (NAFLD)
Elucidating Hepatic Metabolism in Non-alcoholic Fatty Liver Disease
The goal of this observational, cross-sectional, case-control clinical study is to investigate the metabolic adaptations underlying the progression of nonalcoholic fatty liver disease (NAFLD), and to test the hypothesis that…
- Trial name
- ECHO (NCT06942312)
- Testing
- Ketoisocaproic acid breath test, Ammonium Chloride, Bicarbonate de sodium
- Where
- Finland
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- Helsinki University Central Hospital
Melanoma
Efficacy Study of Nivolumab Compared to Ipilimumab in Prevention of Recurrence of Melanoma After Complete Resection of Stage IIIb/c or Stage IV Melanoma
The purpose of this study is to determine whether nivolumab is better than ipilimumab to prevent recurrence of melanoma.
- Trial name
- CheckMate 238 (NCT02388906)
- Testing
- Ipilimumab, Nivolumab
- Where
- 136 sites in United States, Argentina and 23 more
- Volunteers
- 906 people
- Sponsor
- Bristol-Myers Squibb
Alzheimer's Disease
A Study to Verify the Clinical Benefit of Aducanumab in Participants With Early Alzheimer's Disease
The primary objective of this study is to verify the clinical benefit of monthly doses of aducanumab in slowing cognitive and functional impairment as measured by changes in the Clinical Dementia Rating Scale Sum of Boxes…
- Trial name
- ENVISION (NCT05310071)
- Testing
- Aducanumab
- Where
- 265 sites in United States, Australia and 14 more
- Volunteers
- 1,027 people
- Sponsor
- Biogen
Cardiac Arrest With Successful Resuscitation, Hypoxia, Brain
Stepcare Extended Follow-up Substudy
To provide detailed information on long-term outcomes in relation to potential neuroprotection and improvements in recovery for different targets of sedation, temperature, and pressure management in post out of hospital cardiac…
- Conditions
- Cardiac Arrest With Successful Resuscitation, Hypoxia, Brain, Cognitive Impairment, Caregiver Burden
- Trial name
- NCT06207942
- Testing
- Feed back controlled temperature device, High MAP, Deep sedation
- Where
- 34 sites in Australia, Belgium and 8 more
- Volunteers
- 600 people
- Sponsor
- Region Skane
Acute Myeloid Leukemia in Remission, Acute Lymphoblastic Leukemia in Remission
Matched Unrelated vs. Haploidentical Donor for Allogeneic Stem Cell Transplantation in Patients With Acute Leukemia
Primary objective of this open label, two-arm, multicenter, multinational, randomized trial is to compare anti-leukemic activity of allogeneic stem cell transplantation for patients with acute leukemia in complete remission…
- Conditions
- Acute Myeloid Leukemia in Remission, Acute Lymphoblastic Leukemia in Remission, Myelodysplastic Syndromes
- Trial name
- NCT04232241
- Testing
- Allogeneic Stem Cell Transplantation
- Where
- 24 sites in Austria, Czechia and 5 more
- Volunteers
- 167 people
- Sponsor
- Universitätsklinikum Hamburg-Eppendorf
Chronic Kidney Disease, Cardiovascular Diseases
SEDentary Lifestyle, Mortality and Major Adverse Clinical Outcomes in Chronic KIDney Disease
The goal of this study is to learn if a simple home exercise program can benefit patients with advanced chronic kidney disease. There is also an observational part of the study without an exercise program.
- Conditions
- Chronic Kidney Disease, Cardiovascular Diseases, Frailty
- Trial name
- SEDKID (NCT06935786)
- Testing
- EXERCISE TRAINING WITH OR WITHOUT MEDICATION
- Where
- 3 sites in Finland
- Volunteers
- 400 people
- Sponsor
- Turku University Hospital
Respiratory Syncytial Virus Infections
A Study on the Safety and Immune Response to an Unadjuvanted RSV Maternal Vaccine, in High Risk Pregnant Women Aged 15 to 49 Years and Infants Born to the Vaccinated Mothers
The purpose of this study was to evaluate the safety, reactogenicity and immune response of a single intramuscular dose of the respiratory syncytial virus (RSV) maternal vaccine compared to placebo, when administered in the…
- Trial name
- NCT04980391
- Testing
- RSV MAT
- Where
- 35 sites in United States, Brazil and 7 more
- Volunteers
- 384 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Diabetes Mellitus, Type 2
Empa PASS on Urinary Tract Malignancies
The aim of the study is to assess the risk of urinary tract malignancies in patients initiating empagliflozin (free or fixed dose combination) compared to patients initiating a dipeptidyl peptidase-4 (DPP-4) inhibitor.
- Trial name
- NCT03464045
- Testing
- empagliflozin, DPP-4 inhibitors
- Where
- 3 sites in Finland, Sweden and 1 more
- Volunteers
- 344,995 people
- Sponsor
- Boehringer Ingelheim
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.